



Press release from Emotra AB (publ)

Göteborg, September 4, 2018

## **New publication demonstrates the strength of Emotra's test, EDOR®**

**A study conducted by Emotra's Chief of Research and the inventor of EDOR®, Lars-Håkan Thorell, and the biostatistician Karl Wahlin demonstrates how strongly the company's test identifies patients at risk of committing suicide. Their article, "Electrodermal Hyporeactivity as a Marker for Vulnerability to Suicide in Depression", has been accepted for publication in the online journal EC Psychology and Psychiatry, Volume 7 Issue 10, October 01, 2018. Their study is based on an aggregation of three previously conducted blind studies and the results show that hyporeactivity is a strong and clear marker for suicide risk.**

First of all, the results show that the disproportional distribution of suicides among hyporeactive patients is not a coincidence ( $p=0.00058$ ). Secondly, the study shows that the suicide risk associated with hyporeactivity is 25 times higher (Odds Ratio = 25.38) compared with patients in the reactive group. These new results demonstrate that hyporeactivity is a clear and strong marker for suicide risk. Another important conclusion that can be drawn from the study results is that depressed patients whose tests show they are normally reactive belong to a group that is significantly less susceptible to suicide attempts than the average patient who seeks care for depression. This is an observation that further increases the test's clinical usefulness. For Emotra, the publication of this important research paper is welcome documentation and a valuable asset in our marketing efforts. It allows our marketing department to continue to base their work on up-to-date, clear and relevant results.

### **Daniel Poté, our Marketing Manager, says:**

*"The fact that this important research paper was accepted for publication is very valuable to Emotra. Earlier blind studies have shown a clear connection between hyporeactivity and suicide. Since all of the results pointed in the same direction, we realised it would be possible to use the results from these independent studies and, based on them, examine the statistical indicators for increased suicide risk among hyporeactive patients. We have been conducting a review and analysis of the previous studies together with statistical calculations all spring. For Emotra, this process has resulted in a scientific article with new data that provide relevant and useful information for clinics. We*

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)



*consciously chose to publish this information in a scientific article in order to secure highly credible and transparent results, which we see as keys for reaching out to the market.”*

**Comments from our R&D Manager Lars-Håkan Thorell:**

*“We needed to tie these previously conducted blind studies together. They have shown the connection between hyporeactivity and suicide risk that I have been aware of for many years and this has been the driving force behind my research since then. My collaboration with the biostatistician Karl Wahlin provided us with an insight into a relevant approach. Being able to use these studies and aggregating their results in a statistically assured way has been very rewarding. These new insights are an important piece of the puzzle and support further analysis of a plausible model that explains how hyporeactivity is connected to suicide risk. The repeated results with a disproportionate amount of suicides and even violent suicide attempts among the hyporeactive group of patients in study after study was also one of the reasons why our EUDOR-A study was designed to not include a control group, but instead be conducted as a wide, naturalistic study that should rather be seen as validation that the method can successfully be used in clinical practice. My expectation and wish is that an increased use of EDOR in clinical practice will lead to more studies being conducted, leading to an expanded knowledge base—knowledge that benefits both science and health care.”*

Emotra continues to work the private psychiatric hospital market in several major European cities. The new study results will help the company to demonstrate how reliable the EDOR® method is and how hyporeactivity is a clear and strong suicide risk marker. Collaboration projects with clinics and research institutes with a scientific profile will continue to be an important condition for our ability to reach out to psychiatric care-based researchers and caregivers. Emotra can contribute both scientific knowledge and technical competence to these collaborations. A number of important research projects are ongoing and we will be reporting on them in the future. Among these is the article from our completed multi-centre study, EUDOR-A. This manuscript is now being compiled by a group of researchers from various countries.

**For further information, please contact:** Claes Holmberg, CEO. Telephone: +46 708 25 45 47, E-mail: [claes@emotra.se](mailto:claes@emotra.se)

*This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on September 4, 2018 under the above contact's supervision.*

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.